Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
129Xe MRI in Idiopathic Pulmonary Fibrosis
NCT02478268Phase 1Completed
- Start
- May 2015
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of hyperpolarized xenon gas in idiopathic pulmonary fibrosis (IPF) (2 arms). Primary endpoint: Ventilation Defect Percentage at 12 months. Started May 2015; status: completed.
02
Drugs
hyperpolarized xenon gas
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT02478268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02478268.